CTLA4 and hepatocellular carcinoma: Fortunately, there are multiple early and advanced stage clinical trials investigating the efficacy of combination therapies, including combining ICIs with TKIs or combining PD1/PDL1 axis inhibitors with CTLA4 inhibitors, which might change the landscape of HCC management for different stages in the near future.